VRPX (Virpax Pharmaceuticals) Selling, General, & Admin. Expense: $6.26 Mil (TTM As of Dec. 2024)


What is Virpax Pharmaceuticals Selling, General, & Admin. Expense?

Virpax Pharmaceuticals VRPX Selling, General, & Admin. Expense is $6.26 Mil as of Dec. 2024.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Virpax Pharmaceuticals's selling, general, & admin. expense for the three months ended in Dec. 2024 was $2.29 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2024 was $6.26 Mil.


Virpax Pharmaceuticals  (OTCPK:VRPX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Virpax Pharmaceuticals Selling, General, & Admin. Expense Related Terms


Virpax Pharmaceuticals Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Virpax Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virpax Pharmaceuticals Selling, General, & Admin. Expense Chart

Virpax Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 2.90 7.19 11.08 11.82 6.26

Virpax Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.84 1.69 1.50 0.78 2.29

VRPX vs SYGGF, SCPX, LADX: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Virpax Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virpax Pharmaceuticals Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virpax Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Virpax Pharmaceuticals's Selling, General, & Admin. Expense falls into.



Virpax Pharmaceuticals Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $6.26 Mil mean?
Virpax Pharmaceuticals (VRPX) has a Selling, General, & Admin. Expense of $6.26 Mil as of Dec. 2024. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Virpax Pharmaceuticals and its competitors.
Is Virpax Pharmaceuticals' Selling, General, & Admin. Expense too high?
Virpax Pharmaceuticals' current Selling, General, & Admin. Expense is $6.26 Mil.
How does Virpax Pharmaceuticals' Selling, General, & Admin. Expense compare to SYGGF and SCPX?
Virpax Pharmaceuticals' Selling, General, & Admin. Expense of $6.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Virpax Pharmaceuticals and its competitors. Virpax Pharmaceuticals's current Selling, General, & Admin. Expense is $6.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virpax Pharmaceuticals stock overvalued right now?
Virpax Pharmaceuticals (VRPX) has a current Selling, General, & Admin. Expense of $6.26 Mil. The current Selling, General, & Admin. Expense is $6.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Virpax Pharmaceuticals (VRPX), the current Selling, General, & Admin. Expense is $6.26 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Virpax Pharmaceuticals Business Description

Address 1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.